Abstract: Disclosed are compositions for transfecting a nucleic acid molecule into a cell and their applications. Specifically, this relates to a composition suitable for transfecting a nucleic acid molecule into a cell, preferably a eukaryotic cell, including (i) at least one compound of general formula (II) or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or an acceptable salt thereof, and (ii) an acceptable excipient, buffering agent, cell culture medium, or transfection medium, wherein Y1, Y2, Y3, Z1, Z2, Z3, Z4, Z5, Z6, Z7, X1, X2, R3, P+, R, T, U and V are as defined in the description. Also disclosed are uses of the composition and to a method for in vitro or ex vivo transfection of live cells.

Abstract: Disclosed are compositions for transfecting a nucleic acid molecule into a cell and their applications. Specifically, this relates to a composition suitable for transfecting a nucleic acid molecule into a cell, preferably a eukaryotic cell, including (i) at least one compound of general formula (I), preferably of general formula (III), or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or an acceptable salt thereof, and (ii) an acceptable excipient, buffering agent, cell culture medium, or transfection medium, wherein Y1, Y2, Y3, Z1, Z2, Z3, X1, X2, R3, P+, R and V are as defined in the description. Also disclosed are uses of the composition and to a method for in vitro or ex vivo transfection of live cells.

Abstract: Disclosed are compositions for transfecting a messenger RNA (mRNA) into a cell and their applications. The present invention is directed to a composition for transfecting a mRNA into a cell including a mRNA, at least one neutral lipid and a cationic lipid of formula (I), wherein R1 R2, R3, R4 and R5, (CH2)n and A? are as defined in the description. Also disclosed are uses of the composition and to a method for in vitro transfection of live cells.

Abstract: The invention relates to compositions comprising double-stranded oligonucleotides of identical or different sequences and/or length, said oligonucleotides having sequences 3?N1N2 . . . Ni-1Ni . . . Nj5? wherein—3?Ni . . . Nj5? is half of a double-stranded 19-28 mer oligonucleotide of sequence complementary to a target nucleic acid sequence present in a living cell, and—3?N1 . . . Ni-15? is a 3-50 mer overhang of sequence allowing oligomerization of said double-stranded oligonucleotide. Compositions of transfection comprising said oligonucleotide compositions and there used for therapeutical application.

Abstract: The invention relates to compositions comprising double-stranded oligonucleotides of identical or different sequences and/or length, said oligonucleotides having sequences 3?N1N2 . . . Ni-1Ni . . . Nj5? wherein—3?Ni . . . Nj5? is half of a double-stranded 19-28 mer oligonucleotide of sequence complementary to a target nucleic acid sequence present in a living cell, and—3?N1 . . . Ni-15? is a 3-50 mer overhang of sequence allowing oligomerisation of said double-stranded oligonucleotide. Compositions of transfection comprising said oligonucleotide compositions and there used for therapeutical application.

Abstract: The invention relates to compositions comprising double-stranded oligonucleotides of identical or different sequences and/or length, said oligonucleotides having sequences 3?N1N2 . . . Ni-1Ni . . . Nj5? wherein—3?Ni . . . Nj5? is half of a double-stranded 19-28mer oligonucleotide of sequence complementary to a target nucleic acid sequence present in a living cell, and—3?N1 . . . Ni-15? is a 3-50mer overhang of sequence allowing oligomerization of said double-stranded oligonucleotide. Compositions of transfection comprising said oligonucleotide compositions and there used for therapeutical application.

Abstract: The invention relates to a method for manipulating, isolating, detecting or amplifying a target nucleic acid in a sample by hybridization with an oligonucleotide-oligocation conjugate, comprising allowing said nucleic acid to react with an oligonucleotide-oligocation conjugate comprising at least A1 and Bj linked together directly or via a linker, wherein. A, is an i-mer oligonucleotides, with i=3 to 50, where Ai is an oligomer with naturally or non naturally occurring nucleobases and/or pentafuranosyl groups and/or native phosphodiester bonds, optionally comprising a marker group. Bj is a j-mer organic oligocation moiety, with j=1 to 50, where B is —HPO3—R1—(NH—R2)n—NH—R3—O—, where R1, R2 and R3 are lower alkylene, identical or different, NH—R2 moieties being identical or different when n is >1; HPO3—R1—CH(X)—R3—O—, where Ri and R3, identical or different, are lower alkylene and X is putrescine, spermidine or spermine residue.

Abstract: The invention relates to compositions of transfection comprising an oligonucleotide and an amphiphilic cationic molecule of formula (I) wherein, —X is N—R1, S or O, R1 being a C1-C4 alkyl radical or an hydroxylated C3-C6 alkyl radical, R2 and R3, identical or different, represent H or a C1-C4 alkyl radical, or R2 and R3 are linked together to form a saturated or unsaturated cycle or a heterocycle having 5 or 6 elements, E is a C1-C5 alkyl spacer, R4 and R5, identical or different, represent saturated or unsaturated, linear or branched, C10-C36 hydrocarbon or fluorocarbon chains, optionally comprising C3-C6 cycloalkyl, A? is a biocompatible anion. The invention relates to compositions active for oligonucleotides delivery into eukaryotic cells in culture, ex vivo or in vivo. The invention relates to compositions of transfection comprising an oligonucleotide active for RNA interference. Such compositions can be used as tools for biological studies or as drugs for therapies.

Abstract: The invention relates to a method for the production of recombinant proteins by eucaryotic cells in synthetic culture media, wherein said eucaryotic cells are transfected with a composition comprising a synthetic transfection reagent based on a polyhydroxylated polyalkyleneimine.

Abstract: The invention relates to a method for manipulating, isolating, detecting or amplifying a target nucleic acid in a sample by hybridization with an oligonucleotide-oligocation conjugate, comprising allowing said nucleic acid to react with an oligonucleotide-oligocation conjugate comprising at least A1 and Bj linked together directly or via a linker, wherein. A, is an i-mer oligonucleotides, with i=3 to 50, where Ai is an oligomer with naturally or non naturally occurring nucleobases and/or pentafuranosyl groups and/or native phosphodiester bonds, optionally comprising a marker group. Bj is a j-mer organic oligocation moiety, with j=1 to 50, where B is —HPO3—R1—(NH—R2)n—NH—R3—O—, where R1, R2 and R3 are lower alkylene, identical or different, NH—R2 moieties being identical or different when n is >1; HPO3—R1—CH(X)—R3—O—, where Ri and R3, identical or different, are lower alkylene and X is putrescine, spermidine or spermine residue.

Abstract: The invention relates to a composition useful as transfection agent, comprising polyamines modified by aromatic amino acids and small double-strand or single-strand RNA active for RNA interference.

Abstract: The invention concerns a method of synthesising and preparing linear polyethylenimine (PEI) for use as a transfection vector, and the product obtained with such a method. It comprises drying a monomer 2-ethyl-2-oxazoline and polymerising said monomer for obtaining poly (2-ethyl-2-oxazoline) (PEOX) by: using acetonitrile as solvent, adding a dried initiator of the reaction of polymerisation, and mixing them altogether, purifying said obtained PEOX by evaporation, while performing at least three times successive washing/precipitation steps with methanol and diethyl ether and corresponding filtrations, in order to obtain (i), by performing 1H-NMR tests, correct identification of said PEOX polymer, confirmation of absence of monomer to a level <1.0% and confirmation of absence of solvent to a level <5.0% and (ii), by performing Gel Permeation Chromatography, a mean of molecular weight (Mw)>23,000 Da and polydispersity (Mw/Mn) of said PEOX<1.5, hydrolysing said PEOX.

Abstract: The invention relates to compositions of transfection comprising an oligonucleotide and an amphiphilic cationic molecule of formula (I) wherein, —X is N—R1, S or O, R1 being a C1-C4 alkyl radical or an hydroxylated C3-C6 alkyl radical, R2 and R3, identical or different, represent H or a C1-C4 alkyl radical, or R2 and R3 are linked together to form a saturated or unsaturated cycle or a heterocycle having 5 or 6 elements, E is a C1-C5 alkyl spacer, R4 and R5, identical or different, represent saturated or unsaturated, linear or branched, C10-C36 hydrocarbon or fluorocarbon chains, optionally comprising C3-C6 cycloalkyl, A- is a biocompatible anion. The invention relates to compositions active for oligonucleotides delivery into eukaryotic cells in culture, ex vivo or in vivo. The invention relates to compositions of transfection comprising an oligonucleotide active for RNA interference. Such compositions can be used as tools for biological studies or as drugs for therapies.

Abstract: The invention relates to a method for the production of recombinant proteins by eucaryotic cells in synthetic culture media, wherein said eucaryotic cells are transfected with a composition comprising a synthetic transfection reagent based on a polyhydroxylated polyalkyleneimine.

Abstract: The invention relates to compositions comprising double-stranded oligonucleotides of identical or different sequences and/or length, said oligonucleotides having sequences 3?N1N2 . . . Ni?1Ni . . . Nj5? wherein—3Ni . . . Nj5? is half of a double-stranded 19-28 mer oligonucleotide of sequence complementary to a target nucleic acid sequence present in a living cell, and—3?N1 . . . Ni?15? is a 3-50 mer overhang of sequence allowing oligomerisation of said double-stranded oligonucleotide. Compositions of transfection comprising said oligonucleotide compositions and there used for therapeutical application.

Abstract: The invention concerns biomaterials comprising a core coated with alternating layers of polyelectrolytes with opposite charges, characterised in that they include one or several biologically active molecules, with molecular weight less than about 10000 Da, said molecules being fixed to one or several layers of polyelectrolytes.

Abstract: A compound consisting essentially of polylysine conjugated to non-charged residues and recognition signals wherein the free amino functions of said polylysine are substituted with non-charged residues and said recognition signals, which non-charged residues consist of gluconalactone and which recognition signals are at least one member of the group consisting of galactoside, mannoside, fucoside, Lewis.sup.x, Lewis.sup.b, oligomannoside, oligolactosamine saccharides and peptide ANP and said conjugated polylysine contains at least 30% unsubstituted free amino functions and a method of transfecting cultured cells.

Abstract: The invention concerns a complex between at least one negatively charged nucleic acid and at least one positively charged polymeric conjugate, the link between the nucleic acid and the polymeric conjugate being electrostatic in nature, the polymeric conjugate containing a polymer formed from monomer components having free NH.sub.3.sup.+ functions of the aforementioned components and being as follows:--the free NH.sub.3.sup.+ functions from the aforementioned components are substituted in a ratio of at least 10%, advantageously from 45% to 70%, particularly 60%, by noncharged residues leading to a reduction of positive charges in comparison to the same nonsubstituted polymeric conjugate, facilitating the release of nucleic acid by the dissociation of the complex,--the aforementioned residues possess in addition the following properties:.fwdarw.they contain at least one hydroxyl group,.fwdarw.they do not correspond to a recognition signal recognized by a cellular membrane receptor,--the free NH.sub.3.sup.